Dechra Pharmaceuticals Stock

DPH

GB0009633180

Delayed London S.E. 02:30:00 2024-01-16 am EST			5-day change	1st Jan Change
3,866.00 ^GBX	-.--%		-.--%	-

Aug. 16	Dechra Pharmaceuticals PLC Announces Appointment of Justine Conway as Chief Corporate Strategy and Business Development Officer	CI
Jun. 25	Dechra Opens New Global Headquarters in Boston and Invests $60,000 in Local Community Partnerships	CI

Valuation: Dechra Pharmaceuticals

Market Cap	4.4B 5.89B 5.27B 4.87B 8.23B 561B 8.37B 58.06B 23.16B 293B 22.1B 21.63B 930B	P/E 2022	64.8x	P/E 2023	-150x
Enterprise Value	4.83B 6.46B 5.79B 5.34B 9.04B 616B 9.18B 63.73B 25.42B 322B 24.26B 23.74B 1,020B	EV / Sales 2022	5.8x	EV / Sales 2023	6.08x
Free-Float	-	Yield 2022	1.3%	Yield 2023	0.34%

* Estimated data More valuation ratios

Latest news: Dechra Pharmaceuticals

Aug. 16	Dechra Pharmaceuticals PLC Announces Appointment of Justine Conway as Chief Corporate Strategy and Business Development Officer	CI
Jun. 25	Dechra Opens New Global Headquarters in Boston and Invests $60,000 in Local Community Partnerships	CI
May. 19	Dechra Veterinary Products LLC Announces FDA Approval Of Cosacthen Cosyntropin Injection For Canine Patients	CI
Mar. 30	Dechra Pharmaceuticals Limited Announces Termination of Jonathan David Lang as Director, Effective March 31, 2026	CI
Mar. 11	Dechra Announces Consolidation Of Its Existing U.S. Office Footprint In Kansas City, Kan. And Portland, Maine	CI
Mar. 11	Dechra Announces Plans to Relocate Its Global Headquarters from Northwich, England, to Boston, Massachusetts	CI
25-10-13	Intervacc Extends Equine Strangles Vaccine Distribution Deal with Dechra Pharmaceuticals	MT
25-10-13	Intervacc and Dechra Extend Distribution Agreement for Intervacc's Equine Strangle Vaccine Strangvac by Two Years	CI
25-09-02	Dechra Pharmaceuticals Limited completed the acquisition of Invetx, Inc. from a group of shareholders for approximately $530 million	CI
25-08-18	Dechra Pharmaceuticals PLC Launches Strangvac in Spain, Portugal and Slovenia	CI
25-06-16	Vaxxinova GmbH acquired Poultry Vaccines Business of Dechra Pharmaceuticals Limited.	CI
25-05-05	Dechra Pharmaceuticals to Launch Intervacc's Horse Vaccine in Finland	MT
25-05-05	Dechra Pharmaceuticals plc Launches Strangvac in Finland	CI

More news

Analysts' recommendations: Dechra Pharmaceuticals

23-06-27	Stifel Downgrades Dechra Pharmaceuticals to Hold from Buy, Lowers PT	MT
23-06-27	Analyst recommendations: Alphabet, Amgen, GSK, Moderna, Smiths Group...
23-06-27	UBS cuts BT'; HSBC starts Smiths with 'hold'	AN
23-03-07	Davy ups Purplebricks; JPMorgan cuts Clarkson	AN
23-01-12	UBS cuts Beazley; Berenberg likes Rio and BHP	AN

More recommendations

Press Releases: Dechra Pharmaceuticals

23-12-27	Form 8.5 (EPT/RI) - Dechra Pharmaceuticals plc	AQ
23-10-30	Dechra Pharmaceuticals : 30 October 2023 Annual Report 2023 (Online)	PU
23-10-17	Dechra Pharmaceuticals : 17 October 2023 Annual Report 2023 ESEF XHTML	PU
23-10-17	Dechra Pharmaceuticals : 17 October 2023 Annual Report 2023	PU
23-09-06	Form 8.3 - Dechra Pharmaceuticals plc	AQ

More press releases

News in other languages: Dechra Pharmaceuticals

24-01-12	BOLETÍN MATINAL : 12 de enero de 2024
23-12-13	Pharma und Gesundheit: weitere Konsolidierung
23-12-12	Farma en gezondheid: consolidatie gaat door
23-12-11	Farmaceutica e salute: continua il consolidamento
23-12-11	Farmacia y salud: La consolidación continúa

More news

Managers and Directors: Dechra Pharmaceuticals

Manager	Title	Age	Since
Jesper Nordengaard CEO	Chief Executive Officer	-	2024-06-09
Paul Sandland DFI	Director of Finance/CFO	46	2019-04-02
Jamie Adams CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Paul Sandland BRD	Director/Board Member	46	2019-10-29
Lawson Macartney BRD	Director/Board Member	68	2016-11-30
Lisa Jane Bright BRD	Director/Board Member	59	2019-01-31

More insiders

Dechra Pharmaceuticals PLC specializes in the manufacturing and marketing of veterinary pharmaceutical products. Net sales break down by family of products as follows: - companion animal products (74.6%); - food producing animal products (11.5%); - equine health products (7.3%); - animal feeds (5.1%); - other (1.5%): products manufactured by third parties. Net sales are distributed geographically as follows: the United Kingdom (8.5%), Germany (9.2%), Europe (31.2%), the United States (37.9%) and other (13.2%).

Employees

Sector

More about the company

3 years	3,768	3,868
5 years	2,473.32	5,405
10 years	1,225	5,525

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/15/24	Ian Page	Free	Chief Executive Officer	18,551	0.0163%
1/15/24	Paul Sandland	Free	Chief Financial Officer	2,293	0.0020%
1/15/24	Ian Page	Buy	Chief Executive Officer	627	0.0006%

	2022	2023
Net sales	682M 912M 817M 753M 1.27B 86.83B 1.3B 8.99B 3.59B 45.44B 3.42B 3.35B 144B	762M 1.02B 912M 842M 1.42B 96.97B 1.45B 10.04B 4.01B 50.75B 3.82B 3.74B 161B
Net income	58.2M 77.83M 69.71M 64.31M 109M 7.41B 111M 767M 306M 3.88B 292M 286M 12.29B	-27.9M -37.31M -33.42M -30.83M -52.17M -3.55B -53.01M -368M -147M -1.86B -140M -137M -5.89B
Net Debt	208M 278M 249M 230M 389M 26.51B 396M 2.74B 1.1B 13.88B 1.04B 1.02B 43.95B	430M 575M 515M 475M 804M 54.77B 817M 5.67B 2.26B 28.67B 2.16B 2.11B 90.79B

Dechra Pharmaceuticals Stock

Stocks

DPH

GB0009633180

Valuation: Dechra Pharmaceuticals

Latest news: Dechra Pharmaceuticals

Analysts' recommendations: Dechra Pharmaceuticals

Press Releases: Dechra Pharmaceuticals

News in other languages: Dechra Pharmaceuticals

Price Extremes

Managers and Directors: Dechra Pharmaceuticals

Latest insider transactions

Financials

Company Profile